Focal and segmental glomerulosclerosis post COVID-19 vaccine
Descripción del Articulo
The vaccine against SARS-CoV-2 has demonstrated proven efficacy to control the disease, rare adverse effects due to this therapy are still being studied, some of them renal. It is suggested that an inadequate immune response could be the cause of glomerular diseases associated with vaccination. We d...
Autores: | , , , , |
---|---|
Formato: | artículo |
Fecha de Publicación: | 2023 |
Institución: | Universidad Nacional Mayor de San Marcos |
Repositorio: | Revistas - Universidad Nacional Mayor de San Marcos |
Lenguaje: | español |
OAI Identifier: | oai:ojs.csi.unmsm:article/25296 |
Enlace del recurso: | https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/25296 |
Nivel de acceso: | acceso abierto |
Materia: | Vacunas contra la COVID-19 Glomerulonefritis Perú Vaccines against COVID-19 Glomerulonephritis Peru |
id |
REVUNMSM_957dd4a18ca7dbf792cb693c043fd7ff |
---|---|
oai_identifier_str |
oai:ojs.csi.unmsm:article/25296 |
network_acronym_str |
REVUNMSM |
network_name_str |
Revistas - Universidad Nacional Mayor de San Marcos |
repository_id_str |
|
dc.title.none.fl_str_mv |
Focal and segmental glomerulosclerosis post COVID-19 vaccine Glomeruloesclerosis focal y segmentaria post vacuna COVID-19 |
title |
Focal and segmental glomerulosclerosis post COVID-19 vaccine |
spellingShingle |
Focal and segmental glomerulosclerosis post COVID-19 vaccine Arellan-Bravo, Luis Vacunas contra la COVID-19 Glomerulonefritis Perú Vaccines against COVID-19 Glomerulonephritis Peru |
title_short |
Focal and segmental glomerulosclerosis post COVID-19 vaccine |
title_full |
Focal and segmental glomerulosclerosis post COVID-19 vaccine |
title_fullStr |
Focal and segmental glomerulosclerosis post COVID-19 vaccine |
title_full_unstemmed |
Focal and segmental glomerulosclerosis post COVID-19 vaccine |
title_sort |
Focal and segmental glomerulosclerosis post COVID-19 vaccine |
dc.creator.none.fl_str_mv |
Arellan-Bravo, Luis León-Gonzales, Robert Chávez-Bustamante, Sarai G. Cerrón Ventocilla, Katterine Jhanet Asato-Higa, Carmen Arellan-Bravo, Luis León-Gonzales, Robert Chávez-Bustamante, Sarai G. Cerrón Ventocilla, Katterine Jhanet Asato-Higa, Carmen |
author |
Arellan-Bravo, Luis |
author_facet |
Arellan-Bravo, Luis León-Gonzales, Robert Chávez-Bustamante, Sarai G. Cerrón Ventocilla, Katterine Jhanet Asato-Higa, Carmen |
author_role |
author |
author2 |
León-Gonzales, Robert Chávez-Bustamante, Sarai G. Cerrón Ventocilla, Katterine Jhanet Asato-Higa, Carmen |
author2_role |
author author author author |
dc.subject.none.fl_str_mv |
Vacunas contra la COVID-19 Glomerulonefritis Perú Vaccines against COVID-19 Glomerulonephritis Peru |
topic |
Vacunas contra la COVID-19 Glomerulonefritis Perú Vaccines against COVID-19 Glomerulonephritis Peru |
description |
The vaccine against SARS-CoV-2 has demonstrated proven efficacy to control the disease, rare adverse effects due to this therapy are still being studied, some of them renal. It is suggested that an inadequate immune response could be the cause of glomerular diseases associated with vaccination. We describe a 26-year-old patient, with no significant history, received immunity from the SARS-CoV-2 vaccine (Sinopharm), after which he began with proteinuria in the nephrotic range. Proteinuria: 24g in 24 hours. Albumin: 2.36 mg/dl. COVID-19 test negative. Renal biopsy was performed with ultrasound guidance, with anatomopathological result of Focal and Segmental Glomerulosclerosis, tip variant, observing 17 glomeruli. The patient was hospitalized and received immunosuppression with pulses of methylprednisolone, oral prednisone 1mg/kg/day, atorvastatin 20mg/day, antiplatelet therapy with ASA 100mg/day, omeprazole 20mg/day, and trimethoprim-sulfamethoxazole prophylaxis. Two weeks later, the patient had a weight loss (10 kg), the edemas decreased significantly. Four weeks after starting treatment, she presented proteinuria <500 mg/day, which at the moment is within normal values. The development of de Novo focal segmental glomerulosclerosis is possible, after administration of the SARS-CoV-2 vaccine, and that responds to the use of corticosteroids. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-09-28 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/25296 10.15381/anales.v84i3.25296 |
url |
https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/25296 |
identifier_str_mv |
10.15381/anales.v84i3.25296 |
dc.language.none.fl_str_mv |
spa |
language |
spa |
dc.relation.none.fl_str_mv |
https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/25296/20026 |
dc.rights.none.fl_str_mv |
Derechos de autor 2023 Anales de la Facultad de Medicina http://creativecommons.org/licenses/by-nc-sa/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Derechos de autor 2023 Anales de la Facultad de Medicina http://creativecommons.org/licenses/by-nc-sa/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidad Nacional Mayor de San Marcos, Facultad de Medicina Humana |
publisher.none.fl_str_mv |
Universidad Nacional Mayor de San Marcos, Facultad de Medicina Humana |
dc.source.none.fl_str_mv |
Anales de la Facultad de Medicina; Vol. 84 No. 3 (2023); 307-310 Anales de la Facultad de Medicina; Vol. 84 Núm. 3 (2023); 307-310 1609-9419 1025-5583 reponame:Revistas - Universidad Nacional Mayor de San Marcos instname:Universidad Nacional Mayor de San Marcos instacron:UNMSM |
instname_str |
Universidad Nacional Mayor de San Marcos |
instacron_str |
UNMSM |
institution |
UNMSM |
reponame_str |
Revistas - Universidad Nacional Mayor de San Marcos |
collection |
Revistas - Universidad Nacional Mayor de San Marcos |
repository.name.fl_str_mv |
|
repository.mail.fl_str_mv |
|
_version_ |
1795238260084047872 |
spelling |
Focal and segmental glomerulosclerosis post COVID-19 vaccineGlomeruloesclerosis focal y segmentaria post vacuna COVID-19Arellan-Bravo, LuisLeón-Gonzales, RobertChávez-Bustamante, Sarai G.Cerrón Ventocilla, Katterine JhanetAsato-Higa, CarmenArellan-Bravo, LuisLeón-Gonzales, RobertChávez-Bustamante, Sarai G.Cerrón Ventocilla, Katterine JhanetAsato-Higa, CarmenVacunas contra la COVID-19GlomerulonefritisPerúVaccines against COVID-19GlomerulonephritisPeruThe vaccine against SARS-CoV-2 has demonstrated proven efficacy to control the disease, rare adverse effects due to this therapy are still being studied, some of them renal. It is suggested that an inadequate immune response could be the cause of glomerular diseases associated with vaccination. We describe a 26-year-old patient, with no significant history, received immunity from the SARS-CoV-2 vaccine (Sinopharm), after which he began with proteinuria in the nephrotic range. Proteinuria: 24g in 24 hours. Albumin: 2.36 mg/dl. COVID-19 test negative. Renal biopsy was performed with ultrasound guidance, with anatomopathological result of Focal and Segmental Glomerulosclerosis, tip variant, observing 17 glomeruli. The patient was hospitalized and received immunosuppression with pulses of methylprednisolone, oral prednisone 1mg/kg/day, atorvastatin 20mg/day, antiplatelet therapy with ASA 100mg/day, omeprazole 20mg/day, and trimethoprim-sulfamethoxazole prophylaxis. Two weeks later, the patient had a weight loss (10 kg), the edemas decreased significantly. Four weeks after starting treatment, she presented proteinuria <500 mg/day, which at the moment is within normal values. The development of de Novo focal segmental glomerulosclerosis is possible, after administration of the SARS-CoV-2 vaccine, and that responds to the use of corticosteroids.La vacuna contra el SARS-CoV-2 ha demostrado eficacia comprobada para el control de la enfermedad, sin embargo, aún se encuentra en estudio los efectos adversos no comunes debido a esta terapia, algunos de tipo renal. Se plantea que una respuesta inmunológica no adecuada podría ser la causa de enfermedades glomerulares asociada a la vaEcunación. Se reporta el caso de una paciente de 26 años, sin antecedentes de importancia, recibió la inmunidad por la vacuna de SARS-CoV-2 (Sinopharm), posterior a ello inició con proteinuria en rango nefrótico (proteinuria: 24gr en 24 horas), además tuvo albúmina de 2,36 mg/dL y tuvo prueba COVID-19 negativo. Se le realizó biopsia renal con guía ecográfica, con resultado anatomo-patológico de glomeruloesclerosis focal y segmentaria, variante de punta, observándose 17 glomérulos. La paciente fue hospitalizada y recibió inmunosupresión con pulsos de metilprednisolona, prednisona vía oral (1mg/kg/día), atorvastatina (20mg/día), antiagregación plaquetaria con AAS (100mg/día), omeprazol (20mg/día) y profilaxis con trimetoprima-sulfametoxazol. Dos semanas después, la paciente, tuvo una baja de peso (10 kg) y los edemas disminuyeron notoriamente. Cuatro semanas de iniciar el tratamiento, presentó proteinuria < 500 mg/día, la cual al momento se encuentra en valores normales. Es posible el desarrollo de una glomeruloesclerosis focal y segmentaria de novo, tras la administración de la vacuna contra el SARS-CoV-2, y que respondió al uso de corticoides.Universidad Nacional Mayor de San Marcos, Facultad de Medicina Humana2023-09-28info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/2529610.15381/anales.v84i3.25296Anales de la Facultad de Medicina; Vol. 84 No. 3 (2023); 307-310Anales de la Facultad de Medicina; Vol. 84 Núm. 3 (2023); 307-3101609-94191025-5583reponame:Revistas - Universidad Nacional Mayor de San Marcosinstname:Universidad Nacional Mayor de San Marcosinstacron:UNMSMspahttps://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/25296/20026Derechos de autor 2023 Anales de la Facultad de Medicinahttp://creativecommons.org/licenses/by-nc-sa/4.0info:eu-repo/semantics/openAccessoai:ojs.csi.unmsm:article/252962023-10-07T22:29:22Z |
score |
13.871978 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).